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ORIGINAL INVESTIGATION
Insulin treatment increases myocardial 
ceramide accumulation and disrupts 
cardiometabolic function
Aimee E. Hodson, Trevor S. Tippetts and Benjamin T. Bikman*
Abstract 
Background: States of hyperinsulinemia, particularly insulin resistance and type 2 diabetes mellitus, are becoming 
remarkably common, with roughly half a billion people likely to suffer from the disorder within the next 15 years. 
Along with this rise has been an associated increased burden of cardiovascular disease. Considering type 2 diabetics 
treated with insulin are more likely to suffer from heart complications, we sought to determine the specific effect of 
insulin on ceramide-dependent cardiometabolic risk factors, including insulin resistance and altered heart mitochon-
drial physiology.
Methods: H9c2 cardiomyocytes and adult mice were treated with insulin with or without myriocin to inhibit cera-
mide biosynthesis. Insulin and glucose changes were tracked throughout the study and mitochondrial bioenergetics 
was determined in permeabilized cardiomyocytes and myocardium.
Results: Herein, we demonstrate that insulin is sufficient to disrupt heart mitochondrial respiration in both isolated 
cardiomyocytes and whole myocardium, possibly by increasing mitochondrial fission. Further, insulin increases cera-
mide accrual in a time-dependent manner, which is necessary for insulin-induced alterations in heart mitochondrial 
respiration and insulin resistance.
Conclusions: Collectively, these observations have two implications. First, they indicate a pathological role of insulin 
in heart complications stemming from mitochondrial disruption. Second, they identify ceramide as a possible media-
tor of insulin-related heart disorders.
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Background
We have known for decades that type 2 diabetes mellitus 
diabetes (T2DM) increases the risk of heart disease [1]. 
Indeed, the observation is so common that this phenom-
enon is referred to as “diabetic heart disease”, bringing 
attention to the fact that cardiovascular complications 
are the most common cause of mortality in those suf-
fering with T2DM [2, 3]. Considering the increasing 
incidence of T2DM worldwide [4], and the remarkable 
number of undiagnosed cases, at least in early stages [5], 
understanding the nature of the relationship between 
these two pathologies may prevent heart disease and pro-
long healthy living among those with T2DM.
Reflective of the prevailing understanding of the eti-
ology of T2DM, a great deal of research efforts have 
focused on glucose and glycemic control as the causal 
factors between T2DM and heart disease [6–10]. This 
focus has elucidated several glucose-related mecha-
nisms, such as the reduction of glucose to sorbitol [11], 
and especially, the formation of advanced glycation end-
products (AGE) and activation of its receptor (RAGE) 
[12–14]. Moreover, whether a consequence of RAGE 
activation or a distinct mechanism, hyperglycemia is 
known to induce inflammation [15]. Similarly, poor gly-
cemic control may disrupt mitochondrial function and 
increase production of reactive oxygen species [16].
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However, while the focus on glucose as a mediating 
mechanism linking T2DM to cardiovascular complica-
tions has yielded valuable insight, it nevertheless ignores 
what may be at least an equally relevant etiological factor 
of T2DM etiology—insulin. Pories and Dohm recently 
posited that excess insulin, not glucose, is the essential 
factor in T2DM onset [17], a position supported by con-
siderable evidence [18]. T2DM is a progressive spectrum 
of insulin resistance, with overt T2DM representing a 
state where insulin secretion, despite being elevated, is no 
longer sufficient to control blood glucose. As some have 
recommended a paradigm shift from looking at diabetes 
as a consequence of hyperinsulinemia rather than hyper-
glycemia, we are prompted to explore the causal relation-
ship between T2DM and heart disease in a similar light.
Previous reports have observed a role for insulin in the 
etiology cardiovascular complications [19]. Importantly, 
insulin therapy, despite adequately controlling blood 
glucose, has been shown to increase mortality in T2DM 
[20]. Similar to glucose-induced mechanisms (e.g., AGE 
formation, etc.), insulin has distinct downstream media-
tors; one mediator may be the sphingolipid ceramide. 
Ceramides are increasingly recognized as an injuri-
ous mediator of heart pathologies [21–25] and we have 
recently found that insulin increases ceramide biosyn-
thesis and accrual in skeletal muscle [26, 27]. In light of 
the evidence suggesting a role for insulin in the etiology 
of heart complications, the purpose of these experiments 
was to determine the effect of insulin on heart ceramides, 




H9c2 cardiomyocytes were maintained in DMEM +10 % 
FBS. For differentiation into myotubes, cells were grown 
to confluency and the medium was replaced with DMEM 
+10 % horse serum (Invitrogen, Grand Island, NY). Myo-
tubes were used for experiments on day 3 of differentia-
tion. Cells were treated with insulin (50  nM; Actrapid; 
Novo Nordisk, Plainsboro, NJ) and myriocin (10  µM; 
Sigma), an inhibitor of serine palmitoyltransferase, at the 
times indicated.
Animals
Sixteen-week-old male C57Bl/6 mice were separated 
into one of four groups (six per group) to receive morn-
ing injections of saline (PBS), insulin (daily; 0.75 U/kg/
BW; Actrapid; Novo Nordisk, Plainsboro, NJ), myriocin 
(thrice weekly; 0.3  mg/kg; Sigma) or both for 28  days 
with free access to water and chow (Harlan 8604) 
throughout the length of the study. After the 28-d treat-
ment, mice underwent intraperitoneal glucose (G7021; 
Sigma-Aldrich, St. Louis, MO) and insulin (Actrapid; 
Novo Nordisk, Plainsboro, NJ) tolerance tests. For both 
tests, mice were fasted for 6 h and received an injection 
of either glucose (1 g/kg body wt) or insulin (0.75 U/kg 
body wt). These are doses that are above the typical rate 
of insulin treatment in type 2 diabetics (0.5  U/kg) [28]. 
Plasma glucose (Bayer Contour glucose meter), insulin 
(ELISA; Crystal Chem Inc.), and adiponectin (Crystal 
Chem Inc.) levels were determined. Studies were con-
ducted in accordance with the principles and procedures 
outlined in the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved 
by the IACUC (Institutional Animal Care and Use Com-
mittee) at Brigham Young University.
Lipid isolation analysis
Lipids were extracted and quantified as described previ-
ously [29]. Briefly, lipids were isolated with chloroform–
methanol (1:2), and after addition of water, the organic 
phase was collected and dried. After resuspension, lipids 
were quantified using a shotgun lipidomics technique on 
a Thermo Scientific LTQ Orbitrap XL mass spectrometer.
Protein analysis
Cell and tissue proteins were analyzed via western blot as 
described previously [29].
Cell and myocardium permeabilization
For cells, H9c2 cardiomyocytes were detached in culture 
dishes with 0.05  % trypsin–EDTA (Sigma) and growth 
medium was added to the culture. Contents were trans-
ferred to a tube and centrifuged for 10  min at 1000×g 
at RT. After removal of supernatant, cells were lifted in 
MiR05 [0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobi-
onate, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 
110  mM sucrose, and g/l BSA (Sigma; A3803) adjusted 
to pH  7.1] plus 1  mg/ml digitonin and gently rocked at 
RT for 5 min before centrifugation at 1000×g for 5 min. 
After discarding supernatant, cells were then suspended 
in 2.2 ml warm MiR05 and transferred to chambers in the 
O2K (Oroboros Instruments, Innsbruck, Austria). Fol-
lowing respiration protocol (outlined below), cells were 
removed from the chambers and used for protein quan-
tification. For myocardial mitochondrial respiration, left 
ventricle was quickly removed from euthanized mice and 
immediately placed in ice-cold buffer X (60 mM K-MES, 
35  mM KCl, 7.23  mM K2EGTA, 2.77  mM CaK2EGTA, 
20 mM imidazole, 20 mM tuarine, 5.7 mM ATP, 15 mM 
PCr, 6.56  mM MgCl2–6H2O, pH  7.1) and trimmed of 
connective tissue. Small fiber bundles were prepared and 
gently separated along their longitudinal axis under a sur-
gical scope (Olympus, ST) to 1–2 mg. Bundles were then 
transferred to a tube with chilled buffer X and 50 μg/ml 
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saponin and rocked at 4  °C for 30  min, then washed in 
buffer Z (105 mM K-MES, 30 mM KCl, 10 mM KH2PO4, 
5  mM MgCl2–6H2O, 0.5  mg/ml BSA, pH  7.1) at 4  °C 
for at least 15  min. Samples were then blotted dry and 
weighed.
Mitochondrial respiration protocol
High-resolution O2 consumption was determined at 
37  °C in permeabilized cells and fiber bundles using the 
Oroboros O2 K Oxygraph with MiR05 respiration buffer. 
Before addition of sample into respiration chambers, a 
baseline respiration rate was determined. After addi-
tion of sample, the chambers were hyperoxygenated to 
~300  nmol/ml. Following this, respiration was deter-
mined by all or parts of the following substrate-uncou-
pler-inhibitor-titration (SUIT) protocol: electron flow 
through complex I was supported by glutamate  +  malate 
(10 and 2  mM, respectively) to determine leak oxy-
gen consumption (GML). Following stabilization, ADP 
(2.5  mM) was added to determine oxidative phospho-
rylation capacity (GMD). Succinate was added (GMSD) 
for complex I  +  II electron flow into the Q-junction. To 
determine full electron transport system capacity in cells 
over oxidative phosphorylation, the chemical uncoupler 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydra-
zone (FCCP) was added (0.05 μM, followed by 0.025 μM 
steps until maximal O2 flux was reached). Mitochondrial 
membrane integrity was tested in all experiments by add-
ing cytochrome c (not shown; 10  μM). Lastly, residual 
oxygen consumption was measured by adding antimycin 
A (2.5 μM) to block complex III action, effectively stop-
ping any electron flow, which provides a baseline rate of 
respiration.
Statistics
Data are presented as the mean  ±  SEM. Data were com-
pared by ANOVA with Tukey’s post hoc analysis (Graph-
pad Prism; La Jolla, CA). Significance was set at p < 0.05.
Results
Insulin increases cardiomyocyte ceramide accrual, which is 
necessary for mitochondrial disruption
We observed a significant time-dependent increase in 
ceramide accrual in cardiomyocytes with insulin treat-
ment (Fig.  1a), which was supported with an increase 



















































































































Fig. 1 Insulin increases ceramide in cardiomyocytes. H9C2 cardiomyocytes were treated with insulin (INS; 50 nM) with or without myriocin (MYR; 
10 μM), an inhibitor of ceramide biosynthesis, for the times indicated (n = 6). Following treatment time, lipids were isolated for analysis of sphin-
golipids via LCMS (a; n = 6) and protein levels of ceramide biosynthetic enzymes determined (b; n = 4). *P < 0.05 for INS vs. other treatments
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and dihydroceramides desaturase 1 (Des1) with insulin 
treatment (Fig.  1b) at 24  h. Whereas 1  h of insulin had 
no effect on ceramides, 6 h of treatment roughly doubled 
ceramide levels, a level maintained, but not significantly 
increased, at 12 and 24 h. With previous mitochondrial-
specific effects of ceramides in mind [23, 25], we next 
determined whether this ceramide accrual had any effect 
on cardiomyocyte mitochondrial bioenergetics. Insulin 
altered mitochondrial respiration in a contrasting and 
time-dependent manner. At 1  h of insulin treatment, 
respiration was increased in cardiomyocytes, but signifi-







































































































Fig. 2 Ceramide inhibition prevents insulin-induced mitochondrial disruption. H9C2 cardiomyocytes were treated with insulin (INS; 50 nM) with 
or without myriocin (MYR; 10 μM), an inhibitor of ceramide biosynthesis, for the times indicated (n = 6). To measure mitochondrial respiration (a), 
cells were treated with: GML, Glutamate (10 mM) + Malate (2 mM); GMD: + ADP (2.5 mM); GMSD, + Succinate (10 mM); GMSF, + FCCP (0.05 μM). 
Respiratory control ratio (RCR; b), Complex II Factor (c), and uncoupling control ratio (UCR; d) were determined by the analysis indicated. *P < 0.05 
for condition vs. control (PBS)
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alterations in respiration were also evident in the reduced 
respiratory control ratio, an overall indication of mito-
chondrial health [30], at longer time points (Fig.  2b). 
Moreover, distinct function of complex II-mediated 
respiration, defined as the CII factor, revealed acutely 
increased (at 1  h) then decreased (at 6 and 24  h) res-
piration rates (Fig.  2c). Overall, uncoupling control 
ratio, calculated as maximal uncoupled respiration by 
FCCP relative to ADP-stimulated state, was comparable 
among all conditions (Fig. 2d). Importantly, inhibition of 
ceramide accrual with myriocin abolished the insulin-
induced decrement in respiration (Fig. 2a–c).
Additionally, we found that insulin altered mitochon-
drial morphology, appearing to increase mitochondrial 
fission (Fig.  3a), which was prevented with ceramide 
inhibition. Drp1 levels were similar among all treatments 
(Fig. 3b). Further, 1 h of insulin treatment was associated 
with an increase in mitochondrial complex III levels, but 
this was lost with 24 h (Fig. 3c).
Insulin treatment increases body mass and causes 
hyperinsulinemia and insulin resistance in mice
To determine whether an in vivo correlate exists to sub-
stantiate our in  vitro findings, we injected adult male 
mice (16  week old) with insulin daily (0.75  mg/kg) for 
28  days. At the conclusion of the 28  days treatment 
period, mice injected with insulin (INS) gained signifi-
cantly more body mass than PBS-injected mice (Fig. 4a); 
however, those injected with insulin (daily) and myriocin 
(thrice weekly; INS  +  MYR) did not gain such mass. 
Moreover, those injected with myriocin alone (MYR) 
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Fig. 3 Insulin treatment affects cardiomyocyte mitochondrial physiology. H9C2 cardiomyocytes were treated with insulin (INS; 50 nM) with or 
without myriocin (MYR; 10 μM), an inhibitor of ceramide biosynthesis, for the times indicated. Following treatment, cells were imaged to determine 
mitochondrial morphology (a; n = 3), and analyzed for Drp1 protein levels (b; n = 4), and mitochondrial complex proteins (c; n = 4). *P < 0.05 for 
INS vs. PBS; #P < 0.05 for INS + MYR vs. INS alone
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tended to increase with INS injection (Fig. 4b; P = 0.072), 
the change was not significant, and was even less remark-
able when controlled for by body mass (Fig.  4c). INS-
injected mice also had higher fasting insulin (Fig. 5a), but 
not glucose (Fig.  5b) over the course of the treatment. 
Further, INS treatment caused compromised glucose and 
insulin tolerance (Fig.  5a, b, respectively), but not with 
ceramide inhibition.
Insulin treatment in mice increases muscle ceramides 
and alters mitochondrial bioenergetics and morphology
28 days of insulin elicited a roughly two-fold increase in 
myocardial ceramide content (Fig. 6a), though myriocin 
co-treatment prevented this effect. This effect was sup-
ported with an increase in heart SPT2 levels (Fig.  6b). 
Moreover, blood adiponectin was robustly inhibited 
with INS and moderately protected with MYR injections 
(Fig.  6c). Functionally, the increased ceramide accrual 
had a demonstrable and deleterious effect on myocardial 
mitochondrial respiration. In particular, overall respira-
tion and RCR was reduced with INS treatment (Fig. 7a, 
b), though CII factor was not significantly changed 
(Fig. 7c). Lastly, we found that myocardial mitochondria 
were smaller with INS treatment compared with all other 
conditions (Fig.  8a, b), though this was not reflected in 
any change in levels of mitochondrial complex proteins 
(Fig.  8c). This effect may be a result of INS-induced 































































Fig. 4 Insulin injections increase body mass, but not heart mass in 
mice. 16-week-old male mice received injections of PBS (daily), insulin 
(INS; daily; 0.75 mg/kg), myriocin (MYR, thrice weekly; 3 mg/kg), or 
INS + MYR for 28 d. Body mass increased in the INS-treated mice only 
(a; n = 6). Heart mass was measured in all mice (b, c; n = 6). *P < 0.05 
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Fig. 5 Chronic insulin injections increase blood insulin and induce 
glucose and insulin intolerance. 16-week-old male mice received 
injections of PBS (daily), insulin (INS; daily; 0.75 mg/kg), myriocin 
(MYR, thrice weekly; 3 mg/kg), or INS + MYR. Blood insulin (a) and 
glucose (b) was tracked weekly. At the conclusion of the study, IP 
glucose (c) and insulin (d) tolerance tests were performed. *P < 0.05 
for INS vs. PBS; #P < 0.05 for INS + MYR vs. INS alone
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Discussion
Type 2 diabetes carries an increased risk of develop-
ing a surprising and increasing number of pathologies. 
Multiples lines of evidence reveal its hand in diseases 
stemming from cognitive [31], reproductive [32], mus-
culoskeletal [33], and cardiovascular disorders [34]. 
However, type 2 diabetes is typified by two key char-
acteristics—hyperglycemia and hyperinsulinemia [35, 
36]—and while the disease has historically been defined 
by blood glucose levels, insulin may be a more sensitive 
and relevant diagnostic [37]. Indeed, a very recent study 
found that higher insulin exposure in type 2 diabetics is 
associated with a threefold increase in cardiovascular 
events [38]. Herein, we demonstrate that chronic insulin 
injections exert a time-specific and ceramide-dependent 
effect on cardiometabolic function, including insulin 
resistance and heart mitochondrial changes.
These studies provide additional insight into the eti-
ology of type 2 diabetes-related heart complications. 
In particular, these results suggest that insulin is an 
important pathogenic mediator and highlight the need 
to regularly measure insulin when evaluating heart dis-
ease risk. Our findings of insulin impacting mitochon-
drial physiology are not new—Parra et al. [39] found that 
insulin increased mitochondrial respiration. However, 
while we tended to see an overall dampening effect of 
insulin on mitochondrial respiration, a notable difference 
between our studies is the length of time; this previous 
report used a 3-h incubation, while we used several time 
points in our in vitro model. Indeed, our data corroborate 
those of Parra et al. [39] when we analyzed mitochondrial 
respiration at 1 h, but not at periods over 6 h. Combined 
with our observations following a 4-week insulin treat-
ment in mice, these data collectively suggest the clinical 
relevance of prolonged increases in insulin.
In mice, we found that prolonged insulin treat-










































































Fig. 6 Insulin injection increases heart ceramides. 16-week-old male 
mice received injections of PBS (daily), insulin (INS; daily; 0.75 mg/
kg), myriocin (MYR, thrice weekly; 3 mg/kg), or INS + MYR. INS treat-
ment increased myocardial ceramide accrual (a) and SPT2 (b). Serum 
adiponectin was also measured (c). *P < 0.05 for condition vs. PBS. 














































































Fig. 7 Chronic insulin injections disrupt myocardial mitochondrial 
function. 16-week-old male mice received injections of PBS (daily), 
insulin (INS; daily; 0.75 mg/kg), myriocin (MYR, thrice weekly; 3 mg/
kg), or INS + MYR. Mitochondrial assessments were determined in 
permeabilized (saponin, 50 µg/ml) myocardium. To measure mito-
chondrial respiration (a), samples were treated with: GML, Glutamate 
(10 mM) + Malate (2 mM); GMD, + ADP (2.5 mM); GMSD, + Succinate 
(10 mM). Respiratory control ratio (RCR; b) and Complex II Factor (c) 
were determined by the analysis indicated. *P < 0.05 for condition vs. 
PBS
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suggesting that insulin alone, independent of other 
variables, is capable of inducing insulin resistance. This 
observation corroborates evidence from several previous 
reports in humans and rodents wherein hyperinsulinemia 
from endogenous (e.g., insulinoma) [40] and exogenous 
(e.g., injections) [26, 41, 42] sources causes insulin resist-
ance. This insulin-desensitizing effect of prolonged 
hyperinsulinemia is likely at least partially mediated via 
ceramide accrual [26]. While it is possible that the insu-
lin-resistant state caused by the insulin treatment in our 
Fig. 8 Chronic insulin injections disrupt myocardial mitochondrial function. 16-week-old male mice received injections of PBS (daily), insulin (INS; 
daily; 0.75 mg/kg), myriocin (MYR, thrice weekly; 3 mg/kg), or INS + MYR. Heart samples were processed for imaging via electron microscopy (a) 
and quantified based on average greatest mitochondrial diameter (b; n = 3). A portion of samples was used to probe for mitochondrial complexes 
(c; n = 3) and Drp1 (D; n = 3). *P < 0.05 for condition vs. PBS
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study exerts some confounding effect on altering heart 
mitochondrial function independent of insulin-induced 
heart ceramide accrual, we nonetheless consider this 
an apparent feature of the prolonged hyperinsulinemia. 
Nevertheless, insulin resistance per se, in the absence of 
the often-accompanying hyperinsulinemia, may be the 
responsible lesion.
In light of the observations by Dohm and Pories [17], 
who implicate hyperinsulinemia in the etiology of T2DM, 
we submit an alternative hypothesis as to the origins of 
diabetic heart disease that should be considered. As 
opposed to heart disease being a consequence of the 
potentially harmful milieu associated with T2DM, per-
haps heart disease and T2DM are each consequences of 
one pathology—hyperinsulinemia. Such a theory is sup-
ported by multiple reports that implicate insulin alone 
in the etiology of both heart disease [43–45] and T2DM 
[46, 47]. Over two decades ago, Haffner et al. [48] won-
dered about the role of insulin and queried whether heart 
disease started before diabetes onset, when insulin, but 
not glucose, is elevated. Their results add to the body of 
evidence that insulin is an important etiological factor in 
heart disease. A significant strength of measuring insulin 
is that it is elevated earlier than glucose in the progres-
sion to frank T2DM [46, 47] allowing not only an earlier 
diagnosis, but also an earlier, and thus more effective, 
intervention. Collectively, these observations emphasize 
the need to measure insulin in routine health screenings.
Altogether, these results highlight the pathogenicity of 
hyperinsulinemia on cardiometabolic function, including 
insulin resistance and heart mitochondria. These findings 
are corroborated by recent work by Marciniak et al. [49] 
who found reduced cardiac mitochondrial function in a 
mouse model of type 2 diabetes, with concomitant hyper-
insulinemia. Interestingly, cardiac mitochondrial func-
tion was largely unaffected in the streptozotocin-induced 
model of type 1 diabetes, which strengthens the insulin-
centric paradigm of altered cardiometabolic health with 
type 2 diabetes. Another finding from Marciniak et  al. 
[49] was that adiponectin was reduced in their model 
of type 2 diabetes, but not type 1, which is a common 
finding in humans [35]. Considering the actions of adi-
ponectin signaling on ceramide metabolism [50] and 
cardiovascular function [51], the reduced adiponectin 
that accompanies most insulin-resistant conditions may 
provide additional explanation into the increased heart 
ceramide accrual and reduced adiponectin we observed 
in our model of directly induced hyperinsulinemia [52].
The purpose of these studies was to explore the effect of 
insulin in altering cardiometabolic function, with a focus on 
two main components: insulin resistance and heart mito-
chondrial dynamics and physiology. However, while our 
findings shed light on the role of insulin in cardiometabolic 
pathologies, they nevertheless fall short of allowing firm 
conclusions concerning cardiovascular health. Thus, a sig-
nificant weakness that will need to be addressed in future 
studies is the lack of analyses to determine a functional 
impairment with the heart in this same context.
Conclusions
Our data suggest two potential therapeutic strategies 
for mitigating the heart disease burden associated with 
states of elevated insulin (e.g., pre-diabetes or T2DM). 
First, drugs to induce insulin sensitization (e.g., met-
formin) should take priority over drugs that induce insu-
lin secretion (e.g., sulfonylurea), which is associated with 
a reduction [53] and increase [54–56] in heart disease 
risk, respectively. Second, ceramide inhibition may prove 
to be an effective deterrent to heart disease risk in vari-
ous conditions, including hyperinsulinemia, as mounting 
evidence suggests inhibition of ceramide biosynthesis is 
effective at protecting cardiovascular health [57–59].
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